Literature DB >> 17670203

Etilefrine use in the management of post-operative chyle leaks in thoracic surgery.

Philippe Guillem1, Ioannis Papachristos, Christophe Peillon, Jean-Pierre Triboulet.   

Abstract

Etilefrine, a sympathomimetic drug, was used 11 times in 10 patients with thoracic (n=8) or abdominal (n=2) chyle leak occurring after thoracic surgical procedures. It was given as a 4.2-5 mg/h intravenous infusion. During the 11 etilefrine administrations, three patients had total parenteral nutrition, three had enteral nutrition, three had oral fat-free diet and medium-chain triglyceride supplementation, and two were fed orally without restriction. Daily chyle flow output decreased in all but one patient who was reoperated. Chyle flow output did not decrease relevantly in one patient who was reoperated. Chylothorax recurred after reoperation and etilefrine then induced significant output decrease. In another patient, etilefrine was stopped despite significant output reduction because of interactions with other sympathomimetic drugs used for heart failure. The mean etilefrine treatment duration was 6.4 days (range 4-7). The mean daily output was from 740 ml before etilefrine infusion to 183 ml on the seventh day of etilefrine use. By inducing contraction of the smooth muscle fibres present in the wall of the main thoracic chyle ducts, etilefrine can be considered as a useful adjunct in the management of post-operative chyle leak.

Entities:  

Year:  2004        PMID: 17670203     DOI: 10.1016/S1569-9293(03)00263-9

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  10 in total

Review 1.  Chylothorax complicating thoracic surgery: conservative or early surgical management?

Authors:  Panagiotis Misthos; Meletios A Kanakis; Achilleas G Lioulias
Journal:  Updates Surg       Date:  2012-01-13

2.  Octreotide for treating chylothorax after cardiac surgery.

Authors:  Dalokay Kilic; Ekber Sahin; Oner Gulcan; Bulent Bolat; Riza Turkoz; Ahmet Hatipoglu
Journal:  Tex Heart Inst J       Date:  2005

Review 3.  Managing complications I: leaks, strictures, emptying, reflux, chylothorax.

Authors:  Ke-Neng Chen
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

Review 4.  Management options for post-esophagectomy chylothorax.

Authors:  Vaibhav Kumar Varshney; Sunita Suman; Pawan Kumar Garg; Subhash Chandra Soni; Pushpinder Singh Khera
Journal:  Surg Today       Date:  2020-09-17       Impact factor: 2.549

5.  Efficacy of octreotide against chylothorax following lateral neck dissection for thyroid cancer: A case report.

Authors:  Noriaki Hayashibara; Toshihisa Ogawa; Eiichi Tsuji; Kazuo Ishizuna
Journal:  Int J Surg Case Rep       Date:  2016-02-27

6.  Effectiveness of etilefrine regimen for chylothorax after esophagectomy with thoracic duct resection.

Authors:  Yu Ohkura; Masaki Ueno; Toshiro Iizuka; Harushi Udagawa
Journal:  Esophagus       Date:  2017-09-14       Impact factor: 4.230

Review 7.  Diagnosis and Management of Lymphatic Disorders in Congenital Heart Disease.

Authors:  Benjamin Kelly; Sheyanth Mohanakumar; Vibeke Elisabeth Hjortdal
Journal:  Curr Cardiol Rep       Date:  2020-10-10       Impact factor: 2.931

Review 8.  Marketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists' arsenal.

Authors:  Panagiota Papanagnou; Panagiotis Baltopoulos; Maria Tsironi
Journal:  Ther Clin Risk Manag       Date:  2015-05-18       Impact factor: 2.423

9.  Neutrophil-to-lymphocyte ratio is prognostic factor of prolonged pleural effusion after pediatric cardiac surgery.

Authors:  Kazuki Yakuwa; Kagami Miyaji; Tadashi Kitamura; Takashi Miyamoto; Minoru Ono; Yukihiro Kaneko
Journal:  JRSM Cardiovasc Dis       Date:  2021-04-19

10.  New Combined Medical Treatment With Etilefrine and Octreotide for Chylothorax After Esophagectomy: A Case Report and Review of the Literature.

Authors:  Yu Ohkura; Masaki Ueno; Toshiro Iizuka; Shusuke Haruta; Tsuyoshi Tanaka; Harushi Udagawa
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.